Method for treating primary hyperparathyroid disorders
View Patent ↗A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
1. A method for treating a primary hyperparathyroid disorder, the method comprising the step of administration of a Clostridial neurotoxin to a sympathetic ganglion which innervates a parathyroid gland of a patient, thereby treating a primary hyperparathyroid disorder.
2. The method of claim 1 , wherein the Clostridial neurotoxin is administered in an amount of between 10 −3 U/kg and 35 U/kg.
3. The method of claim 1 , wherein the Clostridial neurotoxin is a botulinum toxin.
4. The method of claim 3 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
5. The method of claim 3 , wherein the neurotoxin is botulinum toxin type A.
6. A method for treating a primary hyperparathyroid disorder, the method comprising the step of administration of a therapeutically effective amount of a botulinum toxin to sympathetic ganglion which innervates a parathyroid gland of a patient, thereby treating a primary hyperparathyroid disorder.
7. The method of claim 6 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
8. A method for treating primary hyperparathyroidism, the method comprising the step of local administration to a sympathetic ganglion which innervates a parathyroid hormone (PTH) secreting parathyroid cell of a therapeutically effective amount of a botulinum toxin, thereby reducing an excessive parathyroid hormone secretion from the parathyroid cell and treating primary hyperparathyroidism.
9. The method of claim 8 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
10. The method of claim 1 , wherein the sympathetic ganglion is a cervical ganglion.
11. The method of claim 6 , wherein the sympathetic ganglion is a cervical ganglion.
12. The method of claim 8 , wherein the sympathetic ganglion is a cervical ganglion.